Ryoncil: the first FDA-approved mesenchymal cell therapy

For years, one of the most common questions about stem cells was: “Is any of them FDA-approved?” Since December 2024, the answer is yes. The U.S. Food and Drug Administration approved Ryoncil (remestemcel-L), developed by the Australian company Mesoblast, as the first mesenchymal stromal cell therapy authorized in the United States.

What is Ryoncil?

It is made from bone marrow mesenchymal cells from healthy adult donors (allogeneic: they do not come from the patient). The cells are expanded in the lab under pharmaceutical standards and given intravenously.

What is it approved for?

The indication is very specific: steroid-refractory acute graft-versus-host disease in children 2 months of age and older, including adolescents. It is a serious complication that can occur after a bone marrow transplant, when donor cells attack the recipient’s tissues.

Mesenchymal cells are studied in this condition because of their immunomodulatory effect: they help regulate an uncontrolled immune response.

Why is this important news?

• It validates the regulatory path. It shows that a mesenchymal cell therapy can meet the safety and efficacy standards of one of the strictest agencies in the world.
• It is in real-world use. 2026 was its first full year of commercial use in the United States.
• It drives new research. The same technology is being evaluated in phase III studies for adults with the same disease, for chronic low back pain and for heart failure.

What this approval does not mean

One approved therapy does not mean that every stem cell product is approved for every condition. Each product, each cell source and each indication needs its own studies. That is why it is always worth asking the treating physician which product is used, which laboratory makes it and what regulatory backing it has.

In short

Ryoncil marks a turning point: mesenchymal cells went from a lab promise to an approved medicine for a specific use. It is a step that gives more solid ground to regenerative medicine and the research to come.

This content is for informational purposes only and does not replace evaluation by a health professional. It has not been evaluated by the FDA.